CBIO (Crescent Biopharma) Cash-to-Debt : 0.93 (As of Dec. 2024)

View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Crescent Biopharma's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.93.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Crescent Biopharma couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Crescent Biopharma's Cash-to-Debt or its related term are showing as below:

CBIO's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.695
* Ranked among companies with meaningful Cash-to-Debt only.

Crescent Biopharma Cash-to-Debt Historical Data

The historical data trend for Crescent Biopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Crescent Biopharma Cash-to-Debt Chart

Crescent Biopharma Annual Data

Trend

Dec24

Cash-to-Debt

0.93

Crescent Biopharma Semi-Annual Data
	Dec24
Cash-to-Debt	0.93

Competitive Comparison of Crescent Biopharma's Cash-to-Debt

For the Biotechnology subindustry, Crescent Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Crescent Biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Crescent Biopharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	34.766	/	(0	+	37.482)
	=	0.93

Crescent Biopharma's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	34.766	/	(0	+	37.482)
	=	0.93

Crescent Biopharma (NAS:CBIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Crescent Biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescent Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453

Website

https://www.crescentbiopharma.com

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.